TY - JOUR AU - Caggiano, V. AU - Weiss, R. V. AU - Rickert, T. S. AU - Linde-Zwirble, W. T. PY - 2005 DA - 2005// TI - Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy JO - Cancer VL - 103 UR - https://doi.org/10.1002/cncr.20983 DO - 10.1002/cncr.20983 ID - Caggiano2005 ER - TY - JOUR AU - Crawford, J. AU - Dale, D. C. AU - Lyman, G. H. PY - 2004 DA - 2004// TI - Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management JO - Cancer VL - 100 UR - https://doi.org/10.1002/cncr.11882 DO - 10.1002/cncr.11882 ID - Crawford2004 ER - TY - JOUR AU - Kuderer, N. M. AU - Dale, D. C. AU - Crawford, J. AU - Cosler, L. E. AU - Lyman, G. H. PY - 2006 DA - 2006// TI - Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients JO - Cancer VL - 106 UR - https://doi.org/10.1002/cncr.21847 DO - 10.1002/cncr.21847 ID - Kuderer2006 ER - TY - JOUR AU - Lyman, G. H. AU - Kuderer, N. AU - Greene, J. AU - Balducci, L. PY - 1998 DA - 1998// TI - The economics of febrile neutropenia: implications for the use of colony-stimulating factors JO - Eur J Cancer VL - 34 UR - https://doi.org/10.1016/S0959-8049(98)00222-6 DO - 10.1016/S0959-8049(98)00222-6 ID - Lyman1998 ER - TY - JOUR AU - Lyman, G. H. AU - Kuderer, N. M. PY - 2002 DA - 2002// TI - Filgrastim in patients with neutropenia: potential effects on quality of life JO - Drugs VL - 62 UR - https://doi.org/10.2165/00003495-200262001-00005 DO - 10.2165/00003495-200262001-00005 ID - Lyman2002 ER - TY - JOUR AU - Lyman, G. H. AU - Lyman, C. H. AU - Agboola, O. PY - 2005 DA - 2005// TI - Risk models for predicting chemotherapy-induced neutropenia JO - Oncologist VL - 10 UR - https://doi.org/10.1634/theoncologist.10-6-427 DO - 10.1634/theoncologist.10-6-427 ID - Lyman2005 ER - TY - JOUR AU - Weycker, D. AU - Malin, J. AU - Edelsberg, J. AU - Glass, A. AU - Gokhale, M. AU - Oster, G. PY - 2008 DA - 2008// TI - Cost of neutropenic complications of chemotherapy JO - Ann Oncol VL - 19 UR - https://doi.org/10.1093/annonc/mdm525 DO - 10.1093/annonc/mdm525 ID - Weycker2008 ER - TY - JOUR AU - Weycker, D. AU - Malin, J. AU - Glass, A. AU - Oster, G. PY - 2007 DA - 2007// TI - Economic burden of chemotherapy-related febrile neutropenia JO - J Support Oncol VL - 5 ID - Weycker2007 ER - TY - JOUR AU - Schilling, M. B. P. C. AU - Deeter, R. G. PY - 2011 DA - 2011// TI - Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: A retrospective study JO - Exp Ther Med VL - 2 ID - Schilling2011 ER - TY - STD TI - Kozma CDM, Chia V, Legg L, Barron R: Trends in Neutropenia-Related Inpatient Events. J Oncol Pract. Epub ahead of print, Jan. 31, 2012 ID - ref10 ER - TY - JOUR AU - Smith, T. J. AU - Khatcheressian, J. AU - Lyman, G. H. AU - Ozer, H. AU - Armitage, J. O. AU - Balducci, L. AU - Bennett, C. L. AU - Cantor, S. B. AU - Crawford, J. AU - Cross, S. J. PY - 2006 DA - 2006// TI - 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline JO - J Clin Oncol VL - 24 UR - https://doi.org/10.1200/JCO.2006.06.4451 DO - 10.1200/JCO.2006.06.4451 ID - Smith2006 ER - TY - STD TI - NCCN Clinical Practice Guidelines in Oncology: Myeloid Growth Factors. http://www.nccn.org] UR - http://www.nccn.org ID - ref12 ER - TY - BOOK AU - Morrison VA, C. V. AU - Fridman, M. AU - Delgado, D. J. PY - 2004 DA - 2004// TI - A model to predict chemotherapy-related severe or febrile neutropenia in cycle one among breast cancer and lymphoma patients PB - Proceedings of the American Society of Clinical Oncology Annual Meeting: 2004: 742. Abstract 8068 CY - Alexandria, Virginia ID - Morrison VA2004 ER - TY - JOUR AU - Green, M. D. AU - Koelbl, H. AU - Baselga, J. AU - Galid, A. AU - Guillem, V. AU - Gascon, P. AU - Siena, S. AU - Lalisang, R. I. AU - Samonigg, H. AU - Clemens, M. R. PY - 2003 DA - 2003// TI - A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy JO - Ann Oncol VL - 14 UR - https://doi.org/10.1093/annonc/mdg019 DO - 10.1093/annonc/mdg019 ID - Green2003 ER - TY - JOUR AU - Grigg, A. AU - Solal-Celigny, P. AU - Hoskin, P. AU - Taylor, K. AU - McMillan, A. AU - Forstpointner, R. AU - Bacon, P. AU - Renwick, J. AU - Hiddemann, W. PY - 2003 DA - 2003// TI - Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin’s lymphoma JO - Leuk Lymphoma VL - 44 UR - https://doi.org/10.1080/1042819031000103953 DO - 10.1080/1042819031000103953 ID - Grigg2003 ER - TY - JOUR AU - Holmes, F. A. AU - Jones, S. E. AU - O’Shaughnessy, J. AU - Vukelja, S. AU - George, T. AU - Savin, M. AU - Richards, D. AU - Glaspy, J. AU - Meza, L. AU - Cohen, G. PY - 2002 DA - 2002// TI - Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer JO - Ann Oncol VL - 13 UR - https://doi.org/10.1093/annonc/mdf130 DO - 10.1093/annonc/mdf130 ID - Holmes2002 ER - TY - JOUR AU - Holmes, F. A. AU - O’Shaughnessy, J. A. AU - Vukelja, S. AU - Jones, S. E. AU - Shogan, J. AU - Savin, M. AU - Glaspy, J. AU - Moore, M. AU - Meza, L. AU - Wiznitzer, I. PY - 2002 DA - 2002// TI - Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer JO - J Clin Oncol VL - 20 UR - https://doi.org/10.1200/JCO.20.3.727 DO - 10.1200/JCO.20.3.727 ID - Holmes2002 ER - TY - JOUR AU - Vose, J. M. AU - Crump, M. AU - Lazarus, H. AU - Emmanouilides, C. AU - Schenkein, D. AU - Moore, J. AU - Frankel, S. AU - Flinn, I. AU - Lovelace, W. AU - Hackett, J. PY - 2003 DA - 2003// TI - Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma JO - J Clin Oncol VL - 21 UR - https://doi.org/10.1200/JCO.2003.03.040 DO - 10.1200/JCO.2003.03.040 ID - Vose2003 ER - TY - JOUR AU - Weycker, D. AU - Hackett, J. AU - Edelsberg, J. S. AU - Oster, G. AU - Glass, A. G. PY - 2006 DA - 2006// TI - Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? JO - Ann Pharmacother VL - 40 UR - https://doi.org/10.1345/aph.1G516 DO - 10.1345/aph.1G516 ID - Weycker2006 ER - TY - JOUR AU - Morrison, V. A. AU - Wong, M. AU - Hershman, D. AU - Campos, L. T. AU - Ding, B. AU - Malin, J. PY - 2007 DA - 2007// TI - Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3–4 week chemotherapy regimens in community oncology practices JO - J Manag Care Pharm VL - 13 ID - Morrison2007 ER - TY - JOUR AU - Weycker, D. AU - Malin, J. AU - Kim, J. AU - Barron, R. AU - Edelsberg, J. AU - Kartashov, A. AU - Oster, G. PY - 2009 DA - 2009// TI - Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study JO - Clin Ther VL - 31 UR - https://doi.org/10.1016/j.clinthera.2009.05.019 DO - 10.1016/j.clinthera.2009.05.019 ID - Weycker2009 ER - TY - JOUR AU - Tan, H. T. K. AU - Hurley, D. AU - Daniel, G. AU - Barron, R. AU - Malin, J. PY - 2011 DA - 2011// TI - Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study JO - Curr Med Res Opin VL - 27 UR - https://doi.org/10.1185/03007995.2010.536527 DO - 10.1185/03007995.2010.536527 ID - Tan2011 ER - TY - STD TI - Weycker DMJ, Barron R, Edelsberg J, Kartashov A, Oster G: Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy. Am J Clin Oncol. Epub ahead of print, March 2, 2011 ID - ref23 ER - TY - STD TI - Department of Health and Human Services, Code of Federal Regulations: Code Fed Regul Public Welfare 1995. Protection of human subjects. Washington DC, http://www.hhs.gov/ohrp/policy/ohrpregulations.pdf. Title 45(Sections 46–101 to 46–409):Unknown UR - http://www.hhs.gov/ohrp/policy/ohrpregulations.pdf ID - ref24 ER - TY - JOUR PY - 1996 DA - 1996// TI - Health Insurance Portability and Accountability Act of 1996. Public Law 104–191 JO - US Statut Large VL - 110 ID - ref25 ER - TY - STD TI - WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects. [http://www.wma.net/en/30publications/10policies/b3/index.html] UR - http://www.wma.net/en/30publications/10policies/b3/index.html ID - ref26 ER - TY - JOUR AU - Quan, H. AU - Sundararajan, V. AU - Halfon, P. AU - Fong, A. AU - Burnand, B. AU - Luthi, J. C. AU - Saunders, L. D. AU - Beck, C. A. AU - Feasby, T. E. AU - Ghali, W. A. PY - 2005 DA - 2005// TI - Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data JO - Med Care VL - 43 UR - https://doi.org/10.1097/01.mlr.0000182534.19832.83 DO - 10.1097/01.mlr.0000182534.19832.83 ID - Quan2005 ER - TY - JOUR AU - Fortner, B. V. AU - Okon, T. A. AU - Zhu, L. AU - Tauer, K. AU - Moore, K. AU - Templeton, D. AU - Schwartzberg, L. PY - 2004 DA - 2004// TI - Costs of human resources in delivering cancer chemotherapy and managing chemotherapy-induced neutropenia in community practice JO - Commun Oncol VL - 1 UR - https://doi.org/10.1016/S1548-5315(11)70766-5 DO - 10.1016/S1548-5315(11)70766-5 ID - Fortner2004 ER - TY - JOUR AU - Lyman, G. H. PY - 2006 DA - 2006// TI - Risks and consequences of chemotherapy-induced neutropenia JO - Clin Cornerstone VL - 8 UR - https://doi.org/10.1016/S1098-3597(06)80054-2 DO - 10.1016/S1098-3597(06)80054-2 ID - Lyman2006 ER - TY - STD TI - The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/13/11/prepub UR - http://www.biomedcentral.com/1471-2407/13/11/prepub ID - ref30 ER -